0001104659-21-134407.txt : 20211104 0001104659-21-134407.hdr.sgml : 20211104 20211104162013 ACCESSION NUMBER: 0001104659-21-134407 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20211104 DATE AS OF CHANGE: 20211104 EFFECTIVENESS DATE: 20211104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: EYEGATE PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001372514 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-419911 FILM NUMBER: 211380302 BUSINESS ADDRESS: STREET 1: 271 WAVERLEY OAKS ROAD STREET 2: SUITE 108 CITY: WALTHAM STATE: MA ZIP: 02452 BUSINESS PHONE: 781-788-9043 MAIL ADDRESS: STREET 1: 271 WAVERLEY OAKS ROAD STREET 2: SUITE 108 CITY: WALTHAM STATE: MA ZIP: 02452 D 1 primary_doc.xml X0708 D LIVE 0001372514 EYEGATE PHARMACEUTICALS INC 271 WAVERLEY OAKS ROAD, SUITE 108 WALTHAM MA MASSACHUSETTS 02452 781-788-9043 DELAWARE None None Corporation true Brian Strem 271 Waverley Oaks Road, Suite 108 Waltham MA MASSACHUSETTS 02452 Executive Officer Director President and Chief Executive Officer Sarah Romano 271 Waverley Oaks Road, Suite 108 Waltham MA MASSACHUSETTS 02452 Executive Officer Chief Financial Officer Stephen From 271 Waverley Oaks Road, Suite 108 Waltham MA MASSACHUSETTS 02452 Executive Officer Director Executive Chairman Paul Chaney 271 Waverley Oaks Road, Suite 108 Waltham MA MASSACHUSETTS 02452 Director Aron Shapiro 271 Waverley Oaks Road, Suite 108 Waltham MA MASSACHUSETTS 02452 Director Kenneth Gayron 271 Waverley Oaks Road, Suite 108 Waltham MA MASSACHUSETTS 02452 Director Praveen Tyle 271 Waverley Oaks Road, Suite 108 Waltham MA MASSACHUSETTS 02452 Director Eric Daniels 271 Waverley Oaks Road, Suite 108 Waltham MA MASSACHUSETTS 02452 Executive Officer Chief Development Officer Pharmaceuticals Decline to Disclose 06b false 2021-10-21 false true true This Form D relates to the issuance of shares of common stock as transaction consideration to the former stockholders of Bayon Therapeutics, Inc. 0 Indefinite 67258 Indefinite 33,798 shares of common stock were issued on October 21, 2021, with the value above based on the closing price on such date. Additional shares may be issuable upon potential earn-out milestones with an aggregate value of up to approximately $7.1 million. false 6 0 0 0 false EYEGATE PHARMACEUTICALS INC /s/ Sarah Romano Sarah Romano Chief Financial Officer 2021-11-04